WO2023245140A2 - Systèmes et procédés de préparation de vaccins utilisant des pathogènes inactivés de manière prévisible - Google Patents

Systèmes et procédés de préparation de vaccins utilisant des pathogènes inactivés de manière prévisible Download PDF

Info

Publication number
WO2023245140A2
WO2023245140A2 PCT/US2023/068541 US2023068541W WO2023245140A2 WO 2023245140 A2 WO2023245140 A2 WO 2023245140A2 US 2023068541 W US2023068541 W US 2023068541W WO 2023245140 A2 WO2023245140 A2 WO 2023245140A2
Authority
WO
WIPO (PCT)
Prior art keywords
source
pathogenic
neutered
virus
compartment
Prior art date
Application number
PCT/US2023/068541
Other languages
English (en)
Other versions
WO2023245140A3 (fr
Inventor
Madhavan Pisharodi
Original Assignee
Perumala Holdings, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/058,185 external-priority patent/US11951164B2/en
Priority claimed from US18/328,463 external-priority patent/US20230302188A1/en
Application filed by Perumala Holdings, LLC filed Critical Perumala Holdings, LLC
Publication of WO2023245140A2 publication Critical patent/WO2023245140A2/fr
Publication of WO2023245140A3 publication Critical patent/WO2023245140A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
    • A62B23/00—Filters for breathing-protection purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/01—Deodorant compositions
    • A61L9/014—Deodorant compositions containing sorbent material, e.g. activated carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
    • A61L9/18—Radiation
    • A61L9/20—Ultra-violet radiation
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
    • A62B11/00—Devices for reconditioning breathing air in sealed rooms
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F13/00—Details common to, or for air-conditioning, air-humidification, ventilation or use of air currents for screening
    • F24F13/28—Arrangement or mounting of filters
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F8/00—Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying
    • F24F8/10—Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F8/00—Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying
    • F24F8/20—Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by sterilisation
    • F24F8/22—Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by sterilisation using UV light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
    • A61L2209/10—Apparatus features
    • A61L2209/14—Filtering means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
    • A61L2209/10—Apparatus features
    • A61L2209/16—Connections to a HVAC unit
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F13/00—Details common to, or for air-conditioning, air-humidification, ventilation or use of air currents for screening
    • F24F13/08—Air-flow control members, e.g. louvres, grilles, flaps or guide plates

Definitions

  • the present invention relates to a method for producing a vaccine from a neutered pathogenic source.
  • the neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light.
  • the neutered SARS-COV-2 viral vaccine is administered through an inhalation pump, orally, or parenterally.
  • the architecture of the neutered inactivated virus can be kept intact or partially destroyed by using graded dosage of the UVC.
  • PPE personal protective equipment
  • mask and face shields have been recommended to protect individuals and control the spread of airborne viruses, such as, SARS-CoV-2 (or the COVID-19) virus.
  • SARS-CoV-2 or the COVID-19 virus.
  • these measures may not be sufficient to contain the spread of the COVID-19 virus especially in confined spaces.
  • Most face masks have questionable ability to block fine virus particles. Tn infected individuals, the masks block the escape of large virus droplets thus forcing them to breath in more and more viruses with each breath and reinfect themselves with the viruses they should be expelling.
  • Social distancing is of questionable value in a facility where people move around because the virus droplets take eight minutes or more to drop from a height of five feet. Inevitably, a virus “halo” from the infected person lies in wait for the next person to pass by. Lockdowns have only temporary value because the virus is still present in the ambient air when the lockdown is lifted.
  • the virus has to be destroyed or neutered and the battle should be preferably outside the body since we do not yet know the long- term complications suffered by individuals who are supposedly “cured” of neither the COVID-19 virus nor the long-term effects of current vaccines.
  • Recent studies have found that the COVID-19 virus and other variants spread not only through close personal contacts but also through long distance and for extended periods through the air. Even if the virus droplets fall down within a six-foot radius, the viruses in these droplets are not destroyed. Instead, these droplets dry up, release the virus particles of about 0.1 micron to float into the air converting rooms, buildings, airplanes, etc. into something similar to smoke filled facilities. Even an N95 mask cannot block these particles completely.
  • the COVID- 19 virus can infect buildings, airplanes, buses, trains and other structures that have inadequate disinfection functionality in the associated air conditioning system or in air conditioners with sluggish air movement.
  • air conditioners can function as a “vector equivalent” for the COVID- 19 virus and other microorganisms.
  • Individuals in confined/enclosed spaces are constantly exposed to this deadly virus every time they inhale the air from such an infected building, structure or conventional mask.
  • Neither the air conditioning system nor a conventional mask may be able to protect these individuals because either the masks cannot block such fine virus particles or the masks that can partially block such particles eventually fail due to overloading.
  • the air conditioner system can be upgraded to protect against the COVID- 19 virus and other microorganisms.
  • One embodiment of the present invention includes a process for developing neutered whole pathogen vaccines involving the destruction of the RNA or DNA of the pathogen by using germicidal UV-C radiation.
  • One embodiment of the present invention is a process for developing neutered whole viral vaccines that utilize the destruction of the RNA or DNA of the virus using germicidal UVC (or UV-C) radiation.
  • the SARS-COV-2 virus can be neutered by destruction of its RNA using UV-C in a dose related manner.
  • Another embodiment of the present invention includes a process of neutering a pathogen in a disinfection unit comprising a housing that is opaque to UVC enclosing a chamber that has (a) a chamber wall that is transparent to UV-C light, (b) a chamber inlet, (c) a chamber outlet, (d) a centralized inner bore, (e) an interior chamber surface facing the inner bore; (f) a UV- C light source positioned adjacent the interior surface; and (g) a helical air flow diverter centralized within the inner bore proximate to the UV-C light source, wherein the helical airflow diverter creates a helical path for the airflow pathway as the airflow pathway proceeds from the chamber inlet to the chamber outlet, resulting in a centrifugal force, pushing contaminants to the periphery close to the UV-C light source.
  • Another embodiment of the present invention includes administering the vaccine derived from a neutered whole virus through a nasal inhalation process.
  • An inhalable vaccine simplifies the application process and can greatly improve the acceptance of the vaccine by the general population.
  • SARS-COV-2 infects the cells by binding its spike on the ACE2 proteins on the cell surface. A neutered virus with its intact spikes will bind to the same ACE2 proteins thereby blocking the virus’ entry into the cell.
  • an inhalation pump comprising: (a) a first half and a second half, wherein each half has a top compartment and an adj oining bottom compartment; (b) a fill line associated with each half, the fill line having a septum on a bottom end and a top end that enters a central bore in the top compartment; (c) each bottom compartment is filled with compressed air and has a moveable end at its bottom end; and (d) each top compartment has a releasable cap at its top end.
  • a method of administering a neutered pathogenic inoculum into a nasal cavity of a patient comprising: (a) preparing a neutered pathogenic inoculum; (b) loading the neutered pathogenic inoculum into a central bore of a top compartment of an inhalation pump, wherein the top compartment has a top end that is capped with a removable cap and a moveable bottom end that adjoins a bottom compartment; (c) fdling the bottom compartment with a compressed air; (d) attaching a syringe to a moveable lower end of the bottom compartment; (e) removing the cap from the top end of the top compartment; and (f) pushing a syringe plunger upward to force the inoculum into a patient’s nostril.
  • a method of quantitating damage to a pathogenic source comprising: (a) preparing a standardized pathogenic source; (b) treating the pathogenic source with a known dosage of UV-C radiation; (c) collecting the UV-C treated pathogenic source; (d) assessing an amount of damage to a genetic material of the UV-C treated pathogenic source; and (e) assessing an amount of damage to one or more proteins of the UV-C treated pathogenic source.
  • FIG. 1 is a schematic representation of the preparation of a standardized virulent viral source.
  • FIG. 2A illustrates an active virus harvested from an active patient with a nasal swab.
  • FIG. 2B illustrates the nasal swab from FIG. 2A being used to infect a cell culture.
  • FIG. 3A illustrates the virus being grown in cell cultures.
  • FIG. 3B is a schematic representation of SARS-COV-2 virus particles.
  • FIG. 4 is a perspective view of one embodiment of a UV-C air disinfection unit.
  • FIGs. 5 A - 5C illustrate a sectional side view of embodiments of the air disinfection unit shown in FIG. 4.
  • FIGs 6A and 6B illustrates the air flow path around a helical air flow diverter in the sectional side view of the air disinfection unit.
  • FIG. 7 shows an isometric view of the helical air flow diverter.
  • FIG. 8A is a perspective view of one embodiment of a UV-C air disinfection unit.
  • FIG. 8B is a perspective view of a side section of the air disinfection unit shown in
  • FIG. 8A is a diagrammatic representation of FIG. 8A.
  • FIG. 8C is an isometric view of the air disinfection unit shown in FIG. 8B with its top lid and bottom lid removed.
  • FIG. 8D illustrates a side view of the air flow path through the disinfection chambers of the air disinfection unit shown in FIG. 8C.
  • FIGs. 9A - 9D illustrate different combinations of reflective surfaces and titanium dioxide layers.
  • FIGs. 9E - 9H illustrate light reflections in an inner bore coated with and without an irregular or crenulated surface.
  • FIG. 10A illustrates one embodiment of an air mover.
  • FIG. 10B illustrates one embodiment of an air disinfection unit interconnected with an air mover.
  • FIG. 11 is a perspective view of one embodiment of a system for titrating a dose- related damage to a pathogen.
  • FIG. 12 illustrates one embodiment of a loading device.
  • FIGs. 13A - 13B illustrate one embodiment of a nasal inhalation pump.
  • the present invention relates to a method for producing a vaccine from a neutered pathogenic source.
  • the neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light.
  • the neutered SARS-COV-2 viral vaccine may be administered though an inhalation pump, orally, or parenterally.
  • One embodiment of the present invention includes a method for producing a vaccine from a neutered pathogenic source
  • the neutered pathogenic source may be a SARS-COV- 2 virus that is neutered with a defined dose of UV-C light.
  • Some embodiments of the invention administer the neutered SARS-COV-2 virus through an inhalation pump, orally, or parenterally.
  • One embodiment of the present invention includes a process for producing a vaccine to a predictably inactivated pathogen, such as a virus.
  • the process comprises standardizing a virulent pathogenic source; titrating the degree of ultraviolet inactivation of the pathogenic source; and preparing an inoculum, or vaccine, to produce or increase immunity to the inactivated pathogenic source.
  • inventions described below include processes for producing a vaccine to a standardized inactivated viral source, but such embodiments may be used to produce vaccines to other pathogens, such as bacteria or other microbes.
  • Another embodiment of the present invention includes an inhalation pump and processes for filing the pump and using it to deliver a vaccine into a person’s nasal cavities.
  • a virus source 28 such as the SARS-COV-2 virus, is harvested from an active patient 22 as shown in FIGs. 2A and 2B or retrieved from a stored viral stock 20 from a laboratory.
  • One embodiment of harvesting a viral source from a patient 22 is to use a cotton swab 24 to swab the nasal passage of the patient and then swirl the virus loaded swab in an appropriate cell culture media 26 to release the virus.
  • the virus is typically replicated via the lytic cycle in host cells in cell culture 30. Once the virus enters the host cell, it makes new virus particles that are released into the extracellular fluid. Thus, numerous virus particles 34 are released into the cell culture media as indicated in FIG. 3A.
  • Viral virulence 40 or activity is generally tested by incubating the virus with cultured cells and observing the virus’ cytopathic effects on the cells microscopically.
  • the standardized viral source 10, or a viral suspension containing a known quantity of virus particles having a known activity per volume, is stored in aliquoted samples.
  • UV-C light is a well-known disinfectant.
  • Many UV-C light emitting devices are available in the marketplace. These devices are used to “sterilize” surgical suites, airports, and other such spaces.
  • the UV-C light has to be strong enough to destroy the microorganisms within a close proximity.
  • the microorganisms have to be exposed to the UV-C light for a sufficient duration of time before they are neutralized.
  • Such high energy UV-C radiation and long exposure to UV-C radiation can injure normal human cells like skin, cornea, and other cells. Therefore, UV-C light should not be allowed to come near hands, face or other area of the skin. Furthermore, exposure of the skin to UV-C radiation can cause skin irritation and other ailments.
  • UV light is an electromagnetic radiation beyond the wavelength of the visible violet or beyond the spectrum that the human eye can see.
  • the UV light itself has a spectrum ranging from a 100 nanometer to 400 nanometers.
  • UV light having wavelengths from 315 nm to 400 nm is called UV-A
  • UV-B from 280 nm to 315 nm
  • UV- C from 200 nm to 280 nm
  • Far UV-C light has a spectrum ranging from 207 nm - 222 nm.
  • UV-C and “far UV-C” are used interchangeably.
  • the earth’s ozone layer blocks the UV-C, but allows UV-A and UV-B to reach earth.
  • UV-A and UV-B can damage human skin and are the ones implicated in sunburn, skin cancer, and an increased risk of cataracts.
  • UV-C from the sunlight cannot normally reach the earth because it is filtered out by the earth’s ozone layer.
  • Far UV-C and UV-C light penetration into the skin is low, but is sufficient to cause some damage.
  • UV-C light penetrates microorganisms and denatures their RNA and/or their DNA, making the reproduction of those microorganisms impossible.
  • UV_dose UV_bulb _power*Exposure_time/(4*pi*UV_bulb_distance A 2.
  • One controllable delivery method is to employ one or more embodiments of the unique UV-C air disinfectant unit described below.
  • a UV-C AIR DISINFECTION UNIT [0056] Disinfection Unit with Single Disinfection Chamber.
  • a UV-C air purification disinfection unit 12 illustrated in FIGs. 4 and 5A - 5B, has an opaque housing 15 with a housing inlet 17 and a housing outlet 19; a disinfectant chamber 52 with a transparent chamber wall 55, a chamber inlet 56, a chamber outlet 58, and a centralized inner bore 68 having an interior chamber surface 59 facing the inner bore; a UV-C light source 62 positioned adjacent the interior surface; and a helical air flow diverter 70 centralized within the inner bore proximal to the UV-C light source, wherein the helical airflow diverter creates a helical airflow path 74 for the air flowing from the chamber inlet to the chamber outlet.
  • FIG. 5A illustrates isometric view of the embodiment with LEDs & inner UV transparent chamber wall but without showing helical air diverter.
  • FIG.5B is similar to FIG 5A with UVC tubes instead of LEDs.
  • FIG.5C depicts an embodiment without inner UV transparent chamber without showing helical air diverter.
  • FIG. 6A shows an embodiment with UVC tubes and helical air diverters without inner UVC transparent chamber wall.
  • FIG. 6B is similar to FIG. 6A with LEDs instead of UVC tubes.
  • a UV impenetrable housing 15 is important to protect the user of the unit and the environment around the unit from leaked UV light.
  • the housing has a top lid 42 and a bottom lid 44.
  • the top lid 42 has a number of holes 47 that allow the transfer of heat from one or more heat sinks to the outside air.
  • the top lid also encloses the top ballasts 43.
  • the bottom lid 44 encloses the bottom ballasts 48 as also shown in FIG. 5A.
  • the dimensions of the unit housing 15 can be varied to ensure the achievement of the desired disinfection of the airflow transversing the disinfection unit 12.
  • the housing 15 may have an optional removable inspection window.
  • the air disinfection unit 12 has a single disinfection chamber 52.
  • the disinfection chamber 52 is configured to house at least one UV light source 62 and a helical air flow diverter 70.
  • the disinfection chamber 52 houses one UV-C light source 20 or a plurality of UV-C light sources.
  • the disinfection chamber with its UV-C lights 62 and helical airflow diverter 70 irradiate the air flowing through the chamber from the chamber inlet 56 to the chamber outlet 58.
  • FIGs. 8A - 8D Another embodiment of an air disinfection unit 100 has multiple disinfection chambers 200 as illustrated in FIGs. 8A - 8D. The number of disinfection chambers may vary depending on the desired level of destruction of the pathogen as the pathogen-bearing air flows through the device.
  • the air disinfection unit 100 has a similar housing to disinfection chamber unit 12.
  • FIGs. 8 A and 8B shows the housing 110 with a housing inlet 115 and a housing outlet 117.
  • the housing 110 has a top lid 120 and a bottom lid 130.
  • the top lid 120 has a number of holes 125 that allow the transfer of heat from one or more heat sinks to the outside air.
  • FIG. 8A shows an optional removable inspection window 180 for each disinfection chamber 200 of the device.
  • the removable inspection window 180 in each disinfection chamber may be used to monitor the operation and viability of the components of the disinfection chamber as well as allowing an operator of the device to access the interior of the disinfection chamber as needed for maintenance of the internal components of the disinfection chamber 200.
  • FIGs. 6A and 6B are isometric views of the interior of the air purification unit 12 and its disinfection chamber 52.
  • the air inlet 56 allows the incoming air 50 to enter the disinfection chamber 52 at one end of the helical air flow diverter 70 and circulate around each rung of the helical air flow diverter 70 until the outgoing disinfected air 60 exits out the air outlet 58.
  • FIG. 8B illustrates an isometric view of the interior of the air disinfection module 100.
  • the module 100 has a number of disinfection chambers 200 between the inlet 115 and the outlet 117.
  • the disinfection chambers 200 are separated by UV transparent chamber walls 215 and enclosed in a UV opaque housing 110.
  • Each disinfection chamber 200 is configured to house at least one UV light source 310 and a helical air flow diverter 320 as shown in FIG. 8C.
  • each disinfection chamber houses a plurality of UV-C light sources, such as the UV- C tubes shown in FIG. 8C.
  • Each disinfection chamber with its UV-C lights 310 and helical airflow diverter 320 irradiates the air flowing through the chamber.
  • the air disinfection unit 100 may be configured with various different dimensions as selected to fit the needs of the user, including variable heights and widths. For example, an increase in the width of the device allows for the inclusion of more disinfection chambers, whereas an increase in the height of each chamber allows for a longer air disinfection path through each disinfection chamber 200.
  • Each disinfection chamber 200 is in fluid communication with its adjacent disinfection chamber(s). As illustrated in FIG. 8D, the solid walls of adjacent disinfection chambers 200 are connected via alternating upper air passages 410 and lower air passages 420 to create a serpentine air flow path from one disinfection chamber to another disinfection chamber along the length of the device (shown in FIG. 8C as 200A to 200F).
  • the helical air flow diverter 320 provides a helical air flow passage within each of the chambers 200. This serpentine air flow path between adjacent disinfection chambers and the helical air flow path within each disinfection chamber (see FIG. 8D) provides increased exposure of the pathogens in the airflow from the inlet 115 to the outlet 117 toUV-C or farUV-C light emitted by the ultraviolet light sources for an extended and optimal duration, with close contact.
  • the internal chamber surfaces 59 or 210 respectively may be partially reflective and partially transparent optionally lined with transparent materials, reflective materials and/or titanium dioxide to concentrate the UV-C and also to make the device more lethal to the microorganisms in the air flow.
  • the reflective and titanium dioxide coatings can be coated one over the other or they can be in alternate up and down longitudinal strips inside the chambers.
  • the surface of these reflecting and titanium dioxide coated walls can be made irregular or crenulated to increase the light ray reflections.
  • FIG. 8D shows the incorporation of reflecting and titanium dioxide coated walls 425 and irregular or crenulated areas (not shown) in the interior disinfection chamber wall 210 to increase the light ray reflections. Looking from the inside of the housing, the observation window 180 can be seen.
  • the air flow path and therefore the time and exposure of the air flow to the UV-C sources 310 within the air disinfection unit may be adjusted by (1) adjusting the number of disinfection chambers 200 in the device, (2) adjusting the height of the disinfection chamber and thus the height of the helical air flow diverter, (3) adjusting the number of helical rungs in the helical air flow diverters, (4) varying the surface on the interior wall of the disinfection chamber with reflecting and/or irregular or crenulated walls to increase the light ray reflections; (5) adjusting the speed of the air flow through the device and/or (6) varying the diameter of the helical rungs to control the proximity of the UVC source to the pathogens.
  • UV Light Source [0067] The number, type, strength and the placement of the UV-C lights 62 in the disinfection chamber 52 will ensure that all microorganisms such as bacteria and viruses in the air flow passing through the disinfection chamber 52 will receive a sufficient UV-C dosage to kill any microorganisms in the air. Likewise, the number, type, strength and the placement of the UV-C lights 310 in each disinfection chamber 200 will ensure that the bacteria and viruses in the air flow passing through the disinfection chamber 100 will receive a sufficient UV-C dosage to disinfect the air flowing through the device.
  • the UV-C light source 62 or 310 can be any type of UV-C light source, such as the UV-C tubes 64 shown in FIG. 5C or the UV-C light strips shown in FIG. 5A.
  • UV-C light sources may include mercury lamps, fluorescent tubes, pulsed xenon lamps, excimer lamps, UV-C LEDs, and UV-C lasers. Once the UV-C light source is selected and the wattage or irradiance is known, the exposure time to achieve the desired dosage can be calculated and the appropriate time for the air path to spend passing through the disinfection chambers in close proximity to the UV-C lights can be determined. In fact, when more than one disinfection chamber is used, different UV-C light sources may be used in the different chambers. Different UV light sources may be selected for the different wavelengths that they produce, their different intensities, their different lifespans, the difference in their heat production, or for any other reason.
  • FIG. 7 One embodiment of the helical air flow diverter 70 is illustrated in FIG. 7.
  • the helical air flow diverter provides a helical air flow passage within the disinfection chamber 52 or 200.
  • the helical air flow diverter fdls most of the empty space in the disinfection chamber as seen in FIGs. 6A and 8C thereby creating an air flow path that circulates around each helical rung in a narrow space between the disinfection chamber wall 55 or 210 and the helical air flow diverter rungs.
  • the air flows from the inlet 56 or 115 to the outlet 58 or 117, it circulates close to the UV-C light source(s) throughout the disinfection chamber(s).
  • the particles including the pathogens in the air are driven very close to the UVC source on the chamber wall due to the centrifugal force.
  • the helical air flow diverter surface 72 may be optionally lined with reflective material and/or titanium dioxide with or without areas of irregular or crenulated surfaces as shown in FIG. 7.
  • the helical air diverter found in the disinfection chamber may have any of a variety of variations: (a) variations in the number of rungs/discs of the diverter, where increases to the number of rungs will further interrupt a direct air flow path and increase the passage time; (b) variations in the air speed in a circular path around the rungs of the air diverter to vary the centrifugal force on the air to provide a closer contact between the pathogens and the UV-C source arranged around the periphery of the chambers; (c) increasing the diameter of the diverter discs, thereby reducing the space between the pathogens and the UV-C sources and the chamber walls; (d) making the chamber more lethal to the pathogens by coating the discs with titanium dioxide and increasing the reflectivity of the surface of the chambers between the UV-C light sources to ensure the
  • the air disinfection unit 100 has multiple interconnected disinfection chambers 200 as seen in FIGs. 8B and 8C.
  • the helical air flow diverter 320 in each of the disinfection chambers 200 provides a helical air flow passage within each disinfection chamber as shown in FIG. 8D. Interlinking the disinfection chambers 200 to create a serpentine air flow path between adjacent disinfection chambers in addition to the helical air flow path within each disinfection chamber 200 (see FIG.
  • the air flow path and therefore the time and exposure of the air flow to the UV-C sources 310 within the device may be adjusted by (1) adjusting the number of disinfection chambers 200 in the device, (2) adjusting the height of the disinfection chamber and thus the height of the helical air flow diverter, (3) adjusting the number of helical rungs in helical air flow diverters, and/or (4) adjusting the speed of the air flow through the device.
  • the standardized pathogenic source is then aerosolized using an automated aerosol device, such as a Biaera Aero3GTM, to produce air droplets of a known size containing a known viral count.
  • the aerosolization is standardized to yield a known droplet size for specified air flow rates into and out of the disinfection device(s).
  • the air delivered to the disinfection device(s) will contain both aerosol droplets and diluter air.
  • the aerosol droplets are programmed to be in the inhalable size range.
  • the air disinfection unit of the present invention relies on the air source to travel through the air disinfection unit to neuter or inactivate the microorganisms in the air.
  • the air purification and disinfection system may utilize an air mover or air circulator, such as an air pump or a fan, in communication with the housing inlet or outlet to ensure a controlled rate of air flow through the air disinfection unit.
  • the helical air path through each disinfection chamber will extend the time that the air is exposed to the UV-C light sources.
  • the time the air spends in the disinfection chambers is further controlled by the speed of air movement through the chambers as controlled by the air mover.
  • the speed of air movement through the system may be adjusted by adjusting the power level going to the air mover.
  • An air mover module 80 may be a standalone module, as illustrated in FIG. 10A, which may be interconnected to one or more air disinfection units via tubing or any other means.
  • the air mover module 80 typically has an inlet 85, an outlet 87, an air mover 82 (such as a pump or fans), and a power supply 84 (such as a battery or a power cord).
  • the air mover module may also be built into an air disinfection unit as shown in FIG. 10B.
  • the air mover controls the movement of the air through the air disinfection units.
  • the air mover functions at different power levels that can be electronically controlled. By altering the power level of the air mover, the air circulation can be made faster or slower.
  • the velocity of the air flow through the disinfection unit(s) will proportionately increase or decrease the dosage of UV-C encountered by any pathogen in the air flow through the disinfection unit(s).
  • the UV-C air disinfection unit described above is a reliable means of delivering a set dosage of UV-C to a pathogen in an air supply that passes through the unit.
  • the dosage can be varied by controlling the intensity of UV-C put out by the UV-C source(s), the number and position of the UV-C sources, the number of disinfection units and/or the number of disinfection chambers per disinfection unit.
  • the dosage can also be varied by controlling the exposure time by varying the air flow velocity through the disinfection unit(s) or controlling the length of the air stream pathway through the unit.
  • Examples of other variations include: varying the strength of the UV-C sources, varying the proximity of the microorganisms in the air flow to the UV-C sources, varying the distance traveled by the air stream, and varying the time and proximity that the air steam is exposed to the UV-C light sources in the disinfection chambers 200 within air disinfection module 100.
  • Aerosolized samples of a standardized virulent pathogenic source will be collected before and after UV-C treatment in the disinfection device(s).
  • UV radiation will destroy the genetic material of the pathogen (i.e. DNA or RNA) before it will destroy any other molecules in the pathogen.
  • a neutered pathogen is defined herein as a pathogen with its genetic material (i.e., its RNA or DNA) destroyed so that it cannot reproduce and yet has some or all of its membrane or structural proteins intact.
  • a ribonucleic virus can be neutered by destruction of its RNA using UV-C in a dose related manner. Using a minimal UV-C dosage for destroying its genetic material allows the virus to retain its morphology and the structural integrity of its proteins.
  • a vaccine derived from an intact neutered virus can generate antibodies to various antigenic regions available in one or more of the viral proteins.
  • any damage to the genetic material and/or proteins of the pathogenic source can be correlated to increases in the UV-C dosage used to treat the pathogenic source.
  • any damage to the genetic material and/or proteins of a standardized SARS-COV-2 source can be correlated to increases in the UV-C dosage used to treat the SARS-COV-2 virus.
  • This information can be used to devise a method of neutering the COVTD-19 virus without destroying its structure, including the nucleocapsid protein or its envelope proteins (the M protein, E protein and S protein). If the S protein retains its integrity after UV-C treatment, then it will continue to be able to engage SARS-COV-2 ACE2 receptors and competitively inhibit the untreated virus’s ability to engage the same ACE2 receptors.
  • UV-C dosage given to an aerosolized standardized SARS-COV-2 viral source 700 will vary the UV-C dosage given to an aerosolized standardized SARS-COV-2 viral source 700 by sending the viral source through a series of disinfection devices that vary in the number or type of their UV-C sources and/or disinfection chambers, or by sending the viral source through the disinfection device(s) at different velocities or flow rates.
  • the dosage of UV-C delivered to the viral source is calculated and the degree of damage to the virus is quantified from samples collected by an automatic sampling apparatus 800 and analyzed for the integrity of the various viral components such as its genetic material (RNA or DNA) and its proteins.
  • the present invention includes a process for developing neutered whole pathogen vaccines involving the destruction of the RNA or DNA of the pathogen by using germicidal UV-C radiation.
  • One embodiment of the present invention is a process for developing neutered whole viral vaccines that utilize the destruction of the RNA or DNA of the virus using germicidal UVC (or UV-C) radiation.
  • the SARS-COV-2 virus can be neutered by destruction of its RNA using UV-C in a dose related manner. This allows the virus to retain its morphology and the structural integrity of its envelope proteins.
  • the major SARS- COV-2 vaccines have been prepared to create antibodies to one or more portions of the S protein. However, the S protein has multiple domains.
  • the vaccine is made only against the Receptor Binding Domain (RBD) of the S protein
  • the antibodies produced are only against one or two peptide portions of the S protein.
  • RBD Receptor Binding Domain
  • SARS-COV-2 is an RNA virus.
  • the SARS-COV-2 virus will try to evade the antibodies produced by a vaccine to one or more antigens used in producing the vaccine.
  • the SARS-COV-2 has three envelope proteins and the nucleocapsid protein around the RNA. If each of these proteins generated one or more antibodies then it would be harder for the virus to mutate enough to avoid all of the antibodies produced.
  • the mutation of the virus to evade all of the antibodies produced to a variety of proteins will be difficult. This is because mutation is sustained and propagated only through progeny. If the mutation does not generate progeny, that particular mutation is discarded. In time, the virus will continue to try and mutate, but will then have to stop. Thus, vaccine evasion by a multi-mutated virus will be significantly reduced.
  • a vaccine derived from an intact neutered virus can generate antibodies to various antigenic regions available in one or more of the viral envelope or capsid proteins providing a full spectrum of antigens capable of eliciting a full spectrum of antibodies.
  • SARS-COV- 2 has several envelope proteins - the spike protein (S protein), the membrane protein, and the envelope protein in addition to the nucleocapsid protein; wherein each of these proteins can potentially independently elicit specific antibodies to one or more antigenic regions in each protein.
  • Another embodiment of the present invention includes a process for producing a vaccine to predictably destroyed architecture of the inactivated pathogen, such as a virus.
  • the process comprises standardizing a virulent pathogenic source; titrating the degree of ultraviolet inactivation of the pathogenic source; preparing an inoculum, or vaccine, to produce or increase immunity to the inactivated pathogenic source.
  • a vaccine derived from an intact neutered virus can generate antibodies to various antigenic regions available in one or more of the viral proteins providing a full spectrum of antigens capable of eliciting a full spectrum of antibodies.
  • SARS-COV-2 has several envelope proteins - the spike protein (S protein), the membrane protein, and the envelope protein, in addition to the nucleocapsid protein; wherein each of these proteins can potentially independently elicit specific antibodies to one or more of their antigenic regions. If antibodies are generated to antigenic regions of more than one protein, then a viral mutation to circumvent one particular antibody might remain unmutated while it tries to mutate against another antibody. For any mutation to prevail and propagate, it has to have successful progeny.
  • the polyvalent vaccine can give similar challenge to the virus. Partial S protein antibodies are even easier to evade by mutation. Imagine S protein-lock has seven levers. The mutations have to cover all seven. If the antigen is only part of S protein, the antibody produced is only against a few of these seven levers. This makes the mutation much easier.
  • SARS-COV-2 The development of polyvalent neutered whole virus vaccine can be explained using SARS-COV-2 as an example.
  • This virus has positive-sense, single strand, RNA combined with nucleoprotein as its core.
  • This type III virus has an envelope made of two main proteins, the M (for membrane or matrix) and E (for envelope) and an “attack” protein projecting out and appropriately called the spike protein.
  • M for membrane or matrix
  • E for envelope
  • the lowest dose of UV-C can just neuter the SARS-COV-2 by denaturing the RNA without damaging the architecture of the virus or the four proteins.
  • This product will have four potential antigens from the four preserved proteins for creating a broad-spectrum antibody reaction.
  • a second possible product will be a neutered virus with one damaged protein. It will not be difficult to measure the sensitivity of the four proteins to UV-C, and by using appropriate dose of UV-C the viral antigen can be with four proteins, three proteins, two proteins and just one protein.
  • RNA Since the RNA is denatured in all four of these products, the resulting whole virus cannot be multiplied in any cell and is not infective. It is difficult to predict which of these four UV-C damaged viruses will make the optimal vaccine. This has to be determined with animal experiments and a determination of risks versus benefits. Common sense dictates that the neutered virus with four antibody-producing proteins will be the best vaccine. In this situation, the virus will have to create mutations against all antibodies at the same time to evade the vaccine. Mutations are “errors” produced during virus multiplications in the cells (accidental evolutionary, random or whatever) but not calculated or intentional. The more viruses in circulation the more chance for mutations. Such mutations take place in each infected person through each virus multiplication cycle. At the peak of COVID-19, the estimated number of mutations generated daily in the world was about 100,000 to 1 million.
  • a neutered SARS-COV-2 virus is like a defanged cobra.
  • a defanged cobra can crawl into crevices and get into a house, but it cannot hurt the inhabitants without its teeth.
  • the neutered SARS-COV-2 virus that retains its morphology, will invade human cells through the same ACE2 entrance gates. Then, the neutered SARS-COV-2 virus would die with no progeny. Additionally, the undamaged proteins released by the dead virus can provide foreign antigens that the body can generate antibodies against. These antibodies can then attack and defeat any future active virus invasions.
  • the multiple antibodies produced against different components of the virus can react with the virus and negate its ability to reproduce and cause illness. Furthermore, the virus will struggle to overcome these multiple protein antibodies. Using a specialized pathogen-killing or pathogen-taming system, vaccines of these four grades can be created. The predictable graded destruction of the pathogens will facilitate the development of reliable and optimal vaccines.
  • a neutered, inactivated live virus vaccine provides the benefits of live vaccines without the risk of the individual getting infected. Attenuated live vaccines tend not to infect the individual; however, the live vaccine can sometimes misbehave and thereby infect an individual.
  • the neutered SARS-COV-2 vaccine is better than inactivated whole virus vaccines as it does not have any side effects from the agents used to inactivate the virus. Also, the virus and its capsid or envelope proteins are not mutilated in the process of neutering it, unlike in the process of inactivating the virus using other methods.
  • the UV-C treated neutered SARS-COV-2 virus behaves like the whole virus in its antigenic potential without any side effects and without causing any infection by accident.
  • a measured amount of a quantifiably damaged pathogen may be prepared as an inoculum or vaccine 800, with or without an adjuvant, and loaded into specialized containers for the administration of the vaccine as shown in FIG. 12.
  • Various embodiments include storing multiple vaccine doses in the specialized container or each container may optionally represent a single vaccine dose.
  • One embodiment of a specialized container is an inhalation pump 900.
  • the vaccine can be administered by injecting a vaccine dose using a regular syringe method, preferably one-half dose into each nostril.
  • Another embodiment includes selecting a neutered whole virus, such as the SARS-COV-2 virus, preparing an inoculum from the neutered virus, and aliquoting the inoculum into inhalation pumps as described below.
  • the specified dose of inoculum is injected into the inhalation pumps 900 using an inoculum loading device 810.
  • the inoculum loading device 810 has an injection arm 815 that has two needle loading lines 820, 822.
  • the loading device 810 has a revolving platform 830 containing a circular ring of openings 835. Each opening 835 is configured to hold an inhalation pump 900 bottom-side up.
  • Each inhalation pump 900 has two fill tubes 912, 914 on opposed sides of the bottom compartments of the inhalation pump.
  • the two loading lines 820, 822 fit securely into the two inhalation pump fill lines 912, 914.
  • the loading device injects a set dosage of vaccine through each loading line 820, 822 into the two inhalation pump fill lines 912, 914 and up into the bore 935 of the two top compartments 909.
  • the inhalation pump fill lines 912, 914 are sealed.
  • the sealed vaccine-filled inhalation pumps are sent through a platform outlet 850 into a refrigerated storage unit 860 to be stored until needed.
  • the vaccine derived from a neutered whole virus can be applied through a nasal inhalation process.
  • An inhalable vaccine simplifies the application process and can greatly improve the acceptance of the vaccine by the general population.
  • the vaccine can be administered by mouth or parenterally.
  • Administering the vaccine through inhalation has another unique advantage. Assuming that the virus is just neutered and its architecture is not destroyed, the remaining “whole virus” will act like a “pseudo virus” with its intact spike proteins. These intact spikes will hopefully engage the ACE2 receptors on the COVID-19 landing ports in the nostrils, pharynx and upper respiratory tract without causing the infection or virus multiplication inside the cell.
  • the inhalation pump 900 has a first half 905 and a second half 907. Each half has a bottom compartment 908 and a top compartment 909. In one embodiment each of the two top compartments 909 are shaped like a nose cannula. Each top compartment has a bore 935 that is filled with vaccine. Optionally each of the nose cannulas may curve backwards about 40 to 60 degrees. This curvature allows the cannula to easily enter the patient’s nasal passages and allows the inhalation pump to pump the vaccine into the posterior 2/3 of each nasal passage. The right cannula is used to pump vaccine into the left nostril and the left cannula is used to pump vaccine into the right nostril.
  • the vaccine is loaded into the two top compartments through tubes 912, 914 that run along the sides of the two bottom compartments as described above.
  • the two nose cannulas have a breakable cap 930 at their tips. Once the cap 930 is removed, the vaccine can be released.
  • Some embodiments of the bottom compartments 908 are tubular with an inner bore 928 fdled with compressed neutral air.
  • the top of the inner bore is sealed with a breakable barrier 926 between the interior of the top compartment containing the vaccine and the bottom compartment 908 containing the compressed air.
  • the bottom end of the inner bore is sealed with a movable end 903 similar to the simple reciprocating end of a syringe plunger.
  • the end 903 is attached to a plunger 902 that fits tightly within the inner bore of the cylindrical bottom compartment 908.
  • the end cap 930 is removed from both of the top compartments and a plunger 902 is pushed upwards through the inner bore 928 of the two bottom compartments toward the top compartments 909.
  • the compressed air in the inner bore 928 of the two bottom compartments becomes even more compressed and the increased pressure breaks the barrier 926 and forces the vaccine into the patient’s nostril.
  • Inhalation pumps 900 can be used to introduce the inoculum or vaccine into the rear two thirds of the nasal passage. Nasal vaccinations generally require a minimal volume of the vaccine to be effective.
  • the inhalation pump 900 with its high vaccine deliverance into the patient’s nostrils will reduce the volume of vaccine required for an active immune response.
  • SARS-COV-2 virus enters the body through the upper airways and spreads to the rest of the body. More specifically, the rear two thirds of the nasal passage is known as the landing place for this virus. This is why one swabs the rear portion of their nasal passage for a proper diagnosis of this virus.
  • the attack on the virus is focused at its first landing place and will be more effective. This will also ensure that the neutered and artificially created “pseudo virus” will engage all the ACE2 entry points on the host cells making the true virus particles lost in the wilderness with no ACE2 entry points in the upper respiratory tract.
  • the vaccine derived from a neutered whole virus can be applied through a nasal inhalation process.
  • An inhalable vaccine simplifies the application process and can greatly improve the acceptance of the vaccine by the general population.
  • a formal storage facility can be created to store the vaccine grade pathogens that can be dispensed into inhalation units, parenteral units.
  • one or more or facilities can be set up to make liquid capsules, tablets or other forms for oral administration.
  • a conveyer belt like arrangement can be devised to load the vaccine into the inhalation units, parenteral administration units or the bottles to contain the oral route units.

Abstract

L'invention concerne un procédé de production d'un vaccin à partir d'une source pathogène rendue neutre. La source pathogène rendue neutre peut être un virus SARS-COV-2 qui est filtré avec une dose définie de lumière UV-C. Le vaccin viral anti-SARS-COV-2 rendu neutre est administré par l'intermédiaire d'une pompe d'inhalation.
PCT/US2023/068541 2022-06-17 2023-06-15 Systèmes et procédés de préparation de vaccins utilisant des pathogènes inactivés de manière prévisible WO2023245140A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263353369P 2022-06-17 2022-06-17
US63/353,369 2022-06-17
US202263359381P 2022-07-08 2022-07-08
US63359381 2022-07-08
US202263401817P 2022-08-29 2022-08-29
US63/401,817 2022-08-29
US18058185 2022-11-22
US18/058,185 US11951164B2 (en) 2021-08-16 2022-11-22 Systems and methods for the preparation of vaccines utilizing predictably inactivated pathogens
US18/328,463 US20230302188A1 (en) 2021-08-16 2023-06-02 Expandable system for purification and disinfection of air
US18328463 2023-06-02

Publications (2)

Publication Number Publication Date
WO2023245140A2 true WO2023245140A2 (fr) 2023-12-21
WO2023245140A3 WO2023245140A3 (fr) 2024-03-14

Family

ID=89191999

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2023/068541 WO2023245140A2 (fr) 2022-06-17 2023-06-15 Systèmes et procédés de préparation de vaccins utilisant des pathogènes inactivés de manière prévisible
PCT/US2023/068538 WO2023245138A1 (fr) 2022-06-17 2023-06-15 Système expansible pour la purification et la désinfection de l'air

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2023/068538 WO2023245138A1 (fr) 2022-06-17 2023-06-15 Système expansible pour la purification et la désinfection de l'air

Country Status (1)

Country Link
WO (2) WO2023245140A2 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09253208A (ja) * 1996-03-21 1997-09-30 Unisia Jecs Corp 鼻腔用投薬器
US8066791B2 (en) * 2007-07-20 2011-11-29 Donaldson Company, Inc. Air cleaner arrangements with internal and external support for cartridge; components; and, methods
SE0901365A1 (sv) * 2009-10-22 2010-07-27 Mahbobeh-Taghinejad Sadabadi Doseringsanordning
EP2327466B1 (fr) * 2009-11-12 2014-08-06 Novomatic AG Purificateur d'air pour éliminer les polluants de l'air dans un flux d'air
DE202010007120U1 (de) * 2010-05-21 2011-09-07 Novomatic Ag Kühlluftreiniger eines Elektronikgeräts
US10858643B2 (en) * 2015-10-30 2020-12-08 Sensor Electronic Technology, Inc. Vaccine preparation using ultraviolet radiation
US20210299300A1 (en) * 2020-03-29 2021-09-30 Dynamics Inc. Systems and methods for increasing work area and performance of uv-c generators
JP2023525761A (ja) * 2020-05-08 2023-06-19 ピシャロディ、マドハバン 空気を浄化するためのシステム、装置、及び方法
US11511013B2 (en) * 2020-05-08 2022-11-29 Madhavan Pisharodi Air purification and disinfection apparatus and methods of use
DE102021003829A1 (de) * 2020-09-06 2022-04-21 Kastriot Merlaku Impfstoff-Generator
US11951164B2 (en) * 2021-08-16 2024-04-09 Perumala Holdings, LLC Systems and methods for the preparation of vaccines utilizing predictably inactivated pathogens

Also Published As

Publication number Publication date
WO2023245138A1 (fr) 2023-12-21
WO2023245140A3 (fr) 2024-03-14

Similar Documents

Publication Publication Date Title
US11951164B2 (en) Systems and methods for the preparation of vaccines utilizing predictably inactivated pathogens
JP5868570B2 (ja) 血液バッグシステム及び血液バッグシステムを用いた血小板濃縮物中の病原体を不活化する方法
Hongzhuan et al. Preparation of the inactivated Newcastle disease vaccine by plasma activated water and evaluation of its protection efficacy
EP2142218A1 (fr) Dispositif protecteur
Lederberg Pandemic as a natural evolutionary phenomenon
CN110869058A (zh) 用于辐照器官灌注液的设备和方法
WO2023245140A2 (fr) Systèmes et procédés de préparation de vaccins utilisant des pathogènes inactivés de manière prévisible
US20240142124A1 (en) System for delivery of inactivated pathogens for contactless passive immunization
US11944771B1 (en) Personal medical device for administering treatment via mucous membrane
US20220314041A1 (en) Airflow UV Quarantine Method and Airborne Infection UV Quarantine Device
Brugnera Junior et al. Biophotonics in health care and its relevance in fighting the coronavirus disease
Leanse et al. Shedding UVC light on Covid-19 to protect dentistry staff and patients
US7404806B2 (en) Hemo-aide
US20230302188A1 (en) Expandable system for purification and disinfection of air
US20230149571A1 (en) Apparatus and Methods for Inactivating Bacteria on Surfaces and Mammalian Tissue
Nunes et al. Inactivation of pathogenic microorganisms on polymeric materials through ozonation
US20220143257A1 (en) Uvc sterilization systems and methods for patient ventilation
US20090047298A1 (en) Immune system stimulant and process of manufacturing the same
RU2796987C1 (ru) Штамм "Ямал" вируса гриппа птиц рода Alphainfluenzavirus вида Influenza A virus подтипа H5N1 для изготовления биопрепаратов для специфической профилактики гриппа птиц типа А подтипа Н5
Prevenslik Swine Influenza in vivo Vaccine by Nanoparticle Treatment
WO2022268720A1 (fr) Génération et administration in situ et en temps réel de vaccins viraux à l'aide d'une inactivation de lumière uv
WO2022090586A1 (fr) Système de recirculation et/ou de conditionnement d'air à utiliser comme vaccination
KR20230090521A (ko) 안티바이러스 시스템, 이를 구비한 방역장비 및 방역장비의 바이러스 제거과정을 통하여 점막백신을 조제하는 의료기기
Pisharodi Portable and Air Conditioner-Based Bio-Protection Devices to Prevent Airborne Infections in Acute and Long-Term Healthcare Facilities, Public Gathering Places, Public Transportation, and Similar Entities
KR20240015049A (ko) 바이러스를 분해, 소멸하는 캐비테이션 방역 시스템 및 이 시스템에 의해 점막백신을 조제하는 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23824839

Country of ref document: EP

Kind code of ref document: A2